CHONG KUN DANG HOLDINGS CORP. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 61,500 KRW | +1.82% |
|
+0.33% | +3.89% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
CHONGKUNDANG HOLDINGS CORP., formerly Chong Kun Dang Pharmaceutical Corp., is a Korea-based company engaged in the investment business. Through its subsidiary, the Company provides pharmaceuticals, including remedies for high blood pressure and high cholesterol, immunosuppressive drugs, antitumor agents, antibiotics, remedies for erectile dysfunction and remedies for obesity. It also produces antitumor agents, antibiotics, digestives, circulation agents, respiratory agents, remedies for endocrine diseases, remedies for skin diseases, functional cosmetics and others, as well as pharmaceutical ingredients. On November 2, 2013, the Company divested its pharmaceutical business into a newly established wholly owned subsidiary. After the divestiture, the Company engages in the investment and holding business.
Sector
Food Processing
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
61,500
KRW
Average target price
63,000
KRW
Spread / Average Target
+2.44%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +3.89% | 213M | |
| +8.20% | 7.78B | |
| +10.20% | 6.52B | |
| -8.10% | 3.67B | |
| -13.13% | 3.44B | |
| -14.57% | 1.17B | |
| +8.34% | 934M | |
| -42.27% | 879M | |
| -18.90% | 836M | |
| -16.45% | 802M |
- Stock Market
- Equities
- A001630 Stock
- News Chong Kun Dang Holdings Corp.
- Chong Kun Dang Pharmaceutical Inks Largest-Ever Technology Transfer Agreement with Novartis
